Garcia, Pamela Soto
Brum, Doralina Guimaraes
Oliveira Jr, Osvaldo N.
Higa, Akemi Martins
Magalhaes Ierich, Jessica Cristiane
Moraes, Ariana de Souza
Shimizu, Flavio Makoto
Okuda-Shinagawa, Nancy M.
Peroni, Luis Antonio
da Gama, Paulo Diniz
Teresa Machini, M.
Leite, Fabio Lima
Total Authors: 12
 Univ Fed Sao Carlos, Dept Phys Chem & Math, Nanoneurobiophys Res Grp, BR-18052780 Sorocaba, SP - Brazil
 Univ Sao Paulo, Inst Trop Med, BR-05403000 Sao Paulo, SP - Brazil
 Sao Paulo State Univ, Dept Neurol Psychol & Psychiat, BR-18618687 Botucatu, SP - Brazil
 Oliveira Jr, Jr., Osvaldo N., Univ Sao Paulo, Sao Carlos Inst Phys, BR-13560970 Sao Carlos, SP - Brazil
 Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508000 Sao Paulo, SP - Brazil
 Rheabiotech Lab Res & Dev, BR-13084791 Campinas, SP - Brazil
 Pontifical Catholic Univ Sao Paulo, BR-18030010 Sorocaba, SP - Brazil
Total Affiliations: 7
Web of Science Citations:
Multiple Sclerosis (MS) is a chronic inflammatory disorder in the central nervous system for which biomarkers for diagnosis still remain unknown. One potential biomarker is the myelin basic protein. Here, a nanoimmunosensor based on atomic force spectroscopy (AFS) successfully detected autoantibodies against the MBP85-99 peptide from myelin basic protein. The nanoimmunosensor consisted of an atomic force microscope tip functionalization with MBP85-99 peptide, which was made to interact with a mica surface coated either with a layer of anti-MBP85-99 (positive control) or samples of cerebrospinal fluid (CSF) from five multiple sclerosis (MS) patients at different stages of the disease and five non-MS subjects. The adhesion forces obtained from AFS pointed to a high concentration of anti-MBP85-99 for the two patients at early stages of relapsing-remitting multiple sclerosis (RRMS), which were indistinguishable from the positive control. In contrast, considerably lower adhesion forces were measured for all the other eight subjects, including three MS patients with longer history of the disease and under treatment, without episodes of acute MS activity. We have also shown that the average adhesion force between MBP85-99 and anti-MBP85-99 is compatible with the value estimated using steered molecular dynamics. Though further tests will be required with a larger cohort of patients, the present results indicate that the nanoimmunosensor may be a simple tool to detect early-stage MS patients and be useful to understand the molecular mechanisms behind MS. (AU)